Thursday, November 5, 2026
Via News Knowledge File

Securities and Exchange Commission

government agency80% conf.·synced Nov 5, 2026

Federal regulatory agency overseeing securities markets

9
sourced metrics
1488
relationships
4
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Rias Over 75 Years Old
89companies
Jan 1, 2025source
Rias Registered Before 2018
7935companies
Jan 1, 2025source
Client Count
68400000clients
Jan 1, 2025source
Employee Count
1000000employees
Jan 1, 2025source
Assets Under Management
144.6trillion_USD
Jan 1, 2025⚠ sources conflictsource
Registered Rias
15870companies
Jan 1, 2025source
Rias Over 50 Years Old
124companies
Jan 1, 2025source
Registered Companies
436companies
Jan 1, 1940source
Account Count
300000accounts
Jan 1, 1940source

Stated objectives

Explore ways to allow 401(k) plan participants to have greater access to alternative assets

source
stated

Recover funds through SEC Whistleblower program; persons with non-public information regarding Coty may receive rewards up to 30% of any successful SEC recovery

source
target: 30 percent of successful recovery stated

Issue an innovation exemption allowing third-party tokenization of public company stocks without issuer consent

source
by 2026-05-23 00:00:00stated

Enable stock tokenization on blockchain through an innovation exemption, allowing 24/7 trading of equities including by third parties without company consent

source
stated

Relationship graph · 1488 connections

regulates
1243
regulated by
206
Employs
17
governs
7
files with
3
contracted by
2
allied with
2
employed by
2

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com